VLON (MKap $52 M) Neue Nasdaq Aktie mit Potenzial (Seite 3)
eröffnet am 16.02.21 19:25:38 von
neuester Beitrag 10.02.23 20:26:23 von
neuester Beitrag 10.02.23 20:26:23 von
Beiträge: 62
ID: 1.342.515
ID: 1.342.515
Aufrufe heute: 1
Gesamt: 8.390
Gesamt: 8.390
Aktive User: 0
ISIN: US3622AW2059 · Symbol: GRI
0,4125
USD
+2,94 %
+0,0118 USD
Letzter Kurs 02:00:00 NYSE
Neuigkeiten
02.02.24 · globenewswire  |
26.01.24 · globenewswire |
27.11.23 · globenewswire |
15.11.23 · globenewswire |
31.10.23 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4500 | +30,32 | |
| 2,7100 | +22,62 | |
| 1,4500 | +22,36 | |
| 2,7500 | +22,22 | |
| 5,5500 | +16,60 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,5900 | -18,04 | |
| 3,3100 | -20,62 | |
| 2,2000 | -21,43 | |
| 5,0000 | -37,34 | |
| 0,9700 | -71,47 |
Beitrag zu dieser Diskussion schreiben
Feedback
trade von schon sehr lange.....gestern und heute zeigen warum...ist unter dem Radar und sicherlich hochriskant , aber wenn man es , wie ich so will lol
Antwort auf Beitrag Nr.: 72.141.378 von sedar am 06.08.22 13:46:36Die letzten News waren doch sehr gut, vor Allem das voll gezeichnete pp.
die letzten tage waren interessant
hab den einen tag befriedigend ( lol) mitgenommen--die spitze von 60 -75 hab ich kaum mit meinen verkaufskursen drin gehabt.
gestern wieder eingedeckt---auch nach Jahrzehnten an der börse ist die bewegung der letzten 3 tage für mich noch immer nicht so richtig nachvollziehbar
hab den einen tag befriedigend ( lol) mitgenommen--die spitze von 60 -75 hab ich kaum mit meinen verkaufskursen drin gehabt.
gestern wieder eingedeckt---auch nach Jahrzehnten an der börse ist die bewegung der letzten 3 tage für mich noch immer nicht so richtig nachvollziehbar
pp ist doch ueberraschenderweise voll durch, und das ueber 1 Dollar.
Warum faellt die eigentlich nur noch??
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update.
Second Quarter 2022 Highlights
Engaged Ladenburg Thalmann & Co. Inc. for an evaluation of strategic alternatives for the Company. The review of strategic alternatives remains ongoing and could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets;
Successfully completed a registered direct offering for gross proceeds of $3.9 million;
Reported additional pharmacodynamics (PD) and pharmacokinetics (PK) results from the previously completed SEAL study evaluating the abuse potential of ADAIR; and
Announced the issuance of a new Japanese patent covering composition of matter and methods of manufacturing for ADAIR.
David Baker, Chief Executive Officer of Vallon, commented, “Over the course of the past quarter we have continued to evaluate strategic alternatives in order to identify the best path forward for the Company. This process has identified a number of promising potential opportunities which we are currently evaluating with support of our advisors and Board of Directors. Additionally, with the $3.9 million of gross proceeds from the registered direct financing and the streamlining of operations, we have provided ourselves with additional capital which we believe will enable us to evaluate viable options to maximize stockholder value going forward.”
Summary of Financial Results for Second Quarter 2022
Net loss was $1.8 million for the quarter ended June 30, 2022.
Research and development expenses were $0.3 million and $1.2 million for the three months ended June 30, 2022 and 2021, respectively. The decrease in research and development expenses was primarily due to a decrease in expenses related to the ADAIR development program.
General and administrative expenses were $1.2 million and $1.1 million for the three months ended June 30, 2022 and 2021, respectively. The increase in general and administrative expenses was primarily due to an increase in in public company expense and consulting fees offset by a decrease in personnel and insurance expense.
In May 2022, the Company completed a registered direct offering of 3,700,000 shares of its common stock, at a purchase price of $1.0632 per share, for gross proceeds of $3.9 million. As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of approximately $7.0 million.
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update.
Second Quarter 2022 Highlights
Engaged Ladenburg Thalmann & Co. Inc. for an evaluation of strategic alternatives for the Company. The review of strategic alternatives remains ongoing and could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets;
Successfully completed a registered direct offering for gross proceeds of $3.9 million;
Reported additional pharmacodynamics (PD) and pharmacokinetics (PK) results from the previously completed SEAL study evaluating the abuse potential of ADAIR; and
Announced the issuance of a new Japanese patent covering composition of matter and methods of manufacturing for ADAIR.
David Baker, Chief Executive Officer of Vallon, commented, “Over the course of the past quarter we have continued to evaluate strategic alternatives in order to identify the best path forward for the Company. This process has identified a number of promising potential opportunities which we are currently evaluating with support of our advisors and Board of Directors. Additionally, with the $3.9 million of gross proceeds from the registered direct financing and the streamlining of operations, we have provided ourselves with additional capital which we believe will enable us to evaluate viable options to maximize stockholder value going forward.”
Summary of Financial Results for Second Quarter 2022
Net loss was $1.8 million for the quarter ended June 30, 2022.
Research and development expenses were $0.3 million and $1.2 million for the three months ended June 30, 2022 and 2021, respectively. The decrease in research and development expenses was primarily due to a decrease in expenses related to the ADAIR development program.
General and administrative expenses were $1.2 million and $1.1 million for the three months ended June 30, 2022 and 2021, respectively. The increase in general and administrative expenses was primarily due to an increase in in public company expense and consulting fees offset by a decrease in personnel and insurance expense.
In May 2022, the Company completed a registered direct offering of 3,700,000 shares of its common stock, at a purchase price of $1.0632 per share, for gross proceeds of $3.9 million. As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of approximately $7.0 million.
Trading Spotlight
Antwort auf Beitrag Nr.: 71.586.534 von ooy am 16.05.22 19:30:20Versteht das Jemand?
Kurs 0,50 trotz KE zu $1.0632??
Ich nicht.
Kurs 0,50 trotz KE zu $1.0632??
Ich nicht.
0,6 nur noch - grausam...
Vallon Pharmaceuticals' stock plunged by more than 70% Monday after the Philadelphia biopharmaceutical company announced disappointing clinical trial results for its experimental treatment of attention deficit hyperactivity disorder.
The company's new drug candidate, ADAIR — an acronym for Abuse Deterrent Amphetamine Immediate Release — is a proprietary abuse-deterrent formulation of dextroamphetamine for the treatment of ADHD. Dextroamphetamine has been used clinically for more than 50 years. It is the same active ingredient used in FDA-approved products for ADHD such as Adderall, Dexedrine, and Vyvanse.
ADAIR is designed to deter patients from crushing it and snorting it, or taking it by other non-oral routes to produce a greater "high," according to Vallon.
Vallon (NASDAQ: VLON) said the study results showed ADAIR did not meet its primary endpoint, which was a significant reduction in what is known as "Emax Drug Liking," a standard parameter used in human abuse liability studies.
The company study involved 52 subjects, all of whom were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.
The company said the study results showed ADAIR generated lower "drug liking" scores when compared to standard dextroamphetamine, but the difference was not statistically significant.
ADAIR did produce more favorable results in secondary endpoints such as intranasal irritability, which the company said suggests that manipulated ADAIR was more irritating and less comfortable to snort than crushed dextroamphetamine.
"While we are disappointed by the primary endpoint results, many of the topline findings are encouraging and provide valuable insight,” said David Baker, CEO of Vallon.
Baker said as the company gains additional insight from further analysis of the clinical trial results it will determine next steps for the development program. He added Vallon does plan to request a formal meeting with the Food and Drug Administration to discuss the results and the potential for an additional study.
Vallon shares were trading at $2.20 per share in mid-morning trading Monday, a 70% drop from Friday's closing price of $7.44.
Founded in 2018, Vallon went public last year raising $18 million through its initial public stock offering.
The company's new drug candidate, ADAIR — an acronym for Abuse Deterrent Amphetamine Immediate Release — is a proprietary abuse-deterrent formulation of dextroamphetamine for the treatment of ADHD. Dextroamphetamine has been used clinically for more than 50 years. It is the same active ingredient used in FDA-approved products for ADHD such as Adderall, Dexedrine, and Vyvanse.
ADAIR is designed to deter patients from crushing it and snorting it, or taking it by other non-oral routes to produce a greater "high," according to Vallon.
Vallon (NASDAQ: VLON) said the study results showed ADAIR did not meet its primary endpoint, which was a significant reduction in what is known as "Emax Drug Liking," a standard parameter used in human abuse liability studies.
The company study involved 52 subjects, all of whom were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.
The company said the study results showed ADAIR generated lower "drug liking" scores when compared to standard dextroamphetamine, but the difference was not statistically significant.
ADAIR did produce more favorable results in secondary endpoints such as intranasal irritability, which the company said suggests that manipulated ADAIR was more irritating and less comfortable to snort than crushed dextroamphetamine.
"While we are disappointed by the primary endpoint results, many of the topline findings are encouraging and provide valuable insight,” said David Baker, CEO of Vallon.
Baker said as the company gains additional insight from further analysis of the clinical trial results it will determine next steps for the development program. He added Vallon does plan to request a formal meeting with the Food and Drug Administration to discuss the results and the potential for an additional study.
Vallon shares were trading at $2.20 per share in mid-morning trading Monday, a 70% drop from Friday's closing price of $7.44.
Founded in 2018, Vallon went public last year raising $18 million through its initial public stock offering.
Market Cap 14.852M bei 7,5 Mill. cash habe ich mal gekauft, es geht ja weiter, dauert nur laenger.
Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
VLON
+6.13%
Vallon Pharmaceuticals Inc.
Mon, March 21, 2022, 6:00 PM
In this article:
VLON
+6.13%
Vallon Pharmaceuticals Inc.
Vallon Pharmaceuticals Inc.
– Study did not meet primary endpoint of significant reduction in Emax Drug Liking for ADAIR vs reference dextroamphetamine, although a trend in favor of ADAIR was observed (p=0.16)
– All pharmacodynamic secondary endpoints met with statistical significance
Philadelphia, PA, March 21, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced topline results from its pivotal SEAL study evaluating ADAIR, a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD).
“First and foremost, I would like to extend our sincere appreciation to our clinical team and CRO partners for their hard work and dedication to execute the study, and to all of the study participants. While we are disappointed by the primary endpoint results, many of the topline findings are encouraging and provide valuable insight,” commented David Baker, President & Chief Executive Officer of Vallon. “As we gain additional insight from further analysis of all study endpoints, we will determine next steps for the development program, including plans to request a formal meeting with the FDA in the coming months and the potential for an additional study.”
The SEAL study (Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), is the Company’s pivotal intranasal human abuse liability study assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. ADAIR was prepared for snorting by a pharmacist using a multi-step technique that had been developed by a professional laboratory and agreed upon by the U.S. Food and Drug Administration (FDA). The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis. The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo. All subjects were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.
VLON
+6.13%
Vallon Pharmaceuticals Inc.
Mon, March 21, 2022, 6:00 PM
In this article:
VLON
+6.13%
Vallon Pharmaceuticals Inc.
Vallon Pharmaceuticals Inc.
– Study did not meet primary endpoint of significant reduction in Emax Drug Liking for ADAIR vs reference dextroamphetamine, although a trend in favor of ADAIR was observed (p=0.16)
– All pharmacodynamic secondary endpoints met with statistical significance
Philadelphia, PA, March 21, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced topline results from its pivotal SEAL study evaluating ADAIR, a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD).
“First and foremost, I would like to extend our sincere appreciation to our clinical team and CRO partners for their hard work and dedication to execute the study, and to all of the study participants. While we are disappointed by the primary endpoint results, many of the topline findings are encouraging and provide valuable insight,” commented David Baker, President & Chief Executive Officer of Vallon. “As we gain additional insight from further analysis of all study endpoints, we will determine next steps for the development program, including plans to request a formal meeting with the FDA in the coming months and the potential for an additional study.”
The SEAL study (Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), is the Company’s pivotal intranasal human abuse liability study assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. ADAIR was prepared for snorting by a pharmacist using a multi-step technique that had been developed by a professional laboratory and agreed upon by the U.S. Food and Drug Administration (FDA). The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis. The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo. All subjects were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.
Durchsuchen
